Complex Diabetic Foot Ulcer with Osteomyelitis: A Case Review and Management Strategy

Recent Trends in Diabetic Foot Ulcer Management

Over the past several years, clinicians have observed a steady rise in the incidence of diabetic foot ulcers complicated by osteomyelitis. This trend parallels the growing prevalence of diabetes and peripheral arterial disease. Multidisciplinary care models—combining podiatry, infectious disease, and vascular surgery—are now standard in many health systems. Advances in imaging, such as MRI and PET/CT, have improved the detection of early bone involvement.

Background: The Pathophysiology of Osteomyelitis in Diabetic Foot

Diabetic neuropathy leads to loss of protective sensation, allowing minor trauma to progress unnoticed. Peripheral ischemia impairs healing, and hyperglycemia compromises immune function. Bacteria, most commonly *Staphylococcus aureus*, can spread from a cutaneous ulcer into underlying bone. When infection reaches the cortex or medullary cavity, osteomyelitis becomes established. The presence of biofilm on necrotic bone complicates eradication and often requires combined surgical and medical therapy.

User Concerns: Challenges Faced by Patients and Clinicians

• Patients worry about amputation risk—the possibility of losing part of the foot or leg is a primary fear, even when limb salvage is possible.
• Healing timelines are uncertain—ulcers can take weeks to months to close, and recurrence rates remain high (30–40% within one year in many series).
• Clinicians struggle with diagnosis—distinguishing soft-tissue infection from osteomyelitis is often difficult without advanced imaging or bone biopsy.
• Antimicrobial resistance—prolonged or repeated antibiotic courses may foster resistant organisms, limiting future treatment options.
• Financial and social burdens—frequent clinic visits, home-care needs, and lost work time affect both patients and healthcare systems.

Likely Impact on Treatment Protocols

• Conservative surgical approaches—more centers are adopting limited debridement and partial foot-sparing resections rather than immediate major amputation.
• Biofilm-targeted therapies—use of antiseptic dressings (e.g., iodine- or silver-based) and negative-pressure wound therapy is becoming common to disrupt biofilm.
• Prolonged antibiotic courses—for osteomyelitis, six to twelve weeks of culture-directed antibiotics is typical, though shorter regimens are under study.
• Earlier revascularization—when peripheral artery disease is present, prompt endovascular or surgical revascularization improves wound healing and reduces amputation rates.

What to Watch Next

• Point-of-care diagnostic tools—handheld MRI and rapid molecular pathogen panels may allow faster, more accurate identification of osteomyelitis and guiding microbes.
• Smart wound dressings—sensors that monitor pH, temperature, or bacterial burden could enable earlier detection of worsening infection.
• Personalized antibiotic regimens—pharmacokinetic modeling might optimize drug dosing for patients with renal impairment or obesity.
• Telemedicine follow-up systems—remote wound photography and structured patient education programs may reduce hospital visits while maintaining outcomes.
• Regenerative approaches—growth factors, stem cell therapies, and advanced skin substitutes are being studied to accelerate closure of complex ulcers.